Center for the Investigation of Factor VIII (FVIII) Immune Response in Patients with Hemophilia A (U54)

Funding Agency:
National Institutes of Health

The goal of this Funding Opportunity Announcement (FOA) is to establish up to four Centers for the Investigation of Factor VIII immunogenicity (FVIII Centers). These Centers will utilize cross-disciplinary science and novel technologies to define the basic mechanisms involved in the development of anti-FVIII neutralizing antibodies, also known as FVIII inhibitors, in patients with congenital hemophilia A.

Applications will also include a Skills Development component to support the development of interdisciplinary research skills and expertise in the next generation of physicians/scientists in the field of hemostasis, including the entire spectrum of blood sciences. One application will be selected from the awarded FVIII Centers to provide a range of administrative support to all awardees through an Administrative Core.  


  • Letter of Intent Due Date(s): June 6, 2017
  • Application Due Date(s): July 6, 2017

RFA-HL-18-014 Expiration Date July 7, 2017

Agency Website



Amount Description

Application budgets may not exceed direct costs of $930,000 per year in fiscal years 2018 through 2022.

The maximum period of support is 5 years.  

Funding Type





Curriculum Development
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

July 6, 2017